In recent years, the oil and gas industry has progressed from using digital technologies for select use cases to making their ...

The surge in machinery patents is driven by the need for technological innovation to improve excavation processes.

Following a recent trial, doctors at The Christie Hospital are optimistic about the study of HMBD-001 in the treatment of ...

Lilly’s offering is expected to surpass Novo’s Wegovy in the space, and, according to a report this week from GlobalData, it ...

Overall EV sales gained 12%, pushing the full-year total to a record 1.3 million, according to forecasts from researcher Cox ...

It’s become evident that a cloud-based IT portfolio brings organisations the greatest promise for providing the type of ...

In a release sent to Rigzone recently, GlobalData said the oil and gas industry has seen a dip in active jobs in 2024 but ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

KOLs interviewed by GlobalData stressed the lack of biologic therapies specifically targeting T2-low asthma.

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

AI-driven adaptive cardiac devices are revolutionizing heart disease treatment by enabling real-time monitoring and dynamic ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.